COMMUNIQUÉS West-GlobeNewswire

HEPHAISTOS secures €10.3 M to reach the clinical stage
16/05/2024
PR: HEPHAISTOS secures €10.3 M to reach the clinical stage HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing. €4.5M seed round led [...]
HEPHAISTOS sécurise 10,3 M€ pour aller jusqu’en clinique
16/05/2024
Communiqué : HEPHAISTOS sécurise 10,3 M€ pour aller jusqu’en clinique HEPHAISTOS-Pharma accueille Elaia qui boucle son tour d’amorçage, sécurisant ainsi un total de 10,3 millions d'euros, entre financements dilutifs et [...]
CloudMD Reports 2023 Results for the Full Year and Fourth Quarter
16/05/2024
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates. Q4 2023 gross profit margin 1 of 39.7% was [...]
Assure & Danam Postpone Corporate Update Call & Webcast Scheduled for May 16
16/05/2024
DENVER, May 15, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced today that the [...]
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
16/05/2024
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]
ONWARD® Medical organise un webinaire pour présenter l’état des lieux de ses activités du premier trimestre 2024
16/05/2024
EINDHOVEN, Pays-Bas, 16 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du mouvement, de la fonction et [...]
DiagnaMed Announces LIFE Offering of up to $650,000
16/05/2024
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is pleased to announce that [...]
Spectral AI Announces Voting Results from 2024 Annual Meeting of Stockholders and the Appointment of Erich Spangenberg to the Board of Directors
16/05/2024
DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
16/05/2024
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, [...]
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
15/05/2024
Reported Full Year 2023 total revenues of 2% growth at €48.5 million Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF [...]
Range Impact Reports 1Q 2024 Financial Results
15/05/2024
CLEVELAND, OHIO, May 15, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, reported [...]
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
15/05/2024
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results [...]
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
15/05/2024
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
15/05/2024
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science [...]
Extendicare Announces 2024 First Quarter Results
15/05/2024
MARKHAM, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2024. Results are presented in Canadian dollars [...]
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15/05/2024
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering [...]
Profound Medical Annual General Meeting of Shareholders Voting Results
15/05/2024
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders that was [...]
Quipt Home Medical Reports Second Quarter Fiscal 2024 Financial Results Posting Revenue Growth of 10% and Adjusted EBITDA Growth of 14%
15/05/2024
• Posts Adjusted EBITDA Margin of 23.3% as a % of Revenue • Announced Normal Course Issuer Bid (“NCIB”) Subsequent to Quarter End CINCINNATI, May 15, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) ( [...]
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
15/05/2024
Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma) United Kingdom (UK) Marketing Authorization [...]

Pages